Lumida
/HAE
⌘K
Haemonetics Corp

Haemonetics Corp

HAE
$102.69USD+1.61%+1.63 today

MARKET CAP

4.7B

P/E (TTM)

28.3x

FWD P/E

DAY RANGE

$101 – $103

52W RANGE

$47
$110

AI Summary

Stalk
StalkMedium

HAE remains in a solid medium-term uptrend anchored by price above the 50- and 200-day SMAs, but short-term EMAs have flattened in a narrow consolidation. The lack of a clear breakout or breakdown suggests waiting for confirmation before new entries. We will stalk pullbacks into the converging 9- and 20-day EMA zone near recent support to align with the Stage 2 advance framework.

  • Q1 2027 revenue $339M (+6% YoY); adj. EPS $1.14 (+4%) beat consensus
  • Raised fiscal 2027 organic growth guidance to 4%–7%
  • Gross margin declined to 60.4% due to software license impacts and cost pressures
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$870.5M$993.2M$1.2B$1.3B$1.4B
YoY %-11.9%+14.1%+17.7%+12.0%+4.0%
P / Sales6.7x3.3x3.6x3.3x2.4x
EV / Sales7.8x4.1x4.4x4.1x3.3x
Gross Profit, Adj.$397.8M$505.5M$615.1M$691.5M$749.0M
YoY %-17.9%+27.1%+21.7%+12.4%+8.3%
Margin %45.7%50.9%52.6%52.8%55.0%
EV / Gross Profit17.0x8.1x8.3x7.8x6.1x
EBITDA, Adj.$174.1M$168.9M$248.0M$269.5M$324.1M
YoY %-32.1%-3.0%+46.8%+8.7%+20.3%
Margin %20.0%17.0%21.2%20.6%23.8%
EV / EBITDA38.8x24.3x20.5x20.1x14.0x
EBIT$89.8M$71.1M$155.7M$162.9M$221.8M
YoY %-5.8%-20.7%+118.8%+4.6%+36.2%
Margin %10.3%7.2%13.3%12.4%16.3%
EV / EBIT75.2x57.7x32.7x33.2x20.5x
Net Income$79.5M$43.4M$115.4M$117.6M$167.7M
YoY %+3.8%-45.4%+166.1%+1.9%+42.6%
Net Margin9.1%4.4%9.9%9.0%12.3%
EPS (GAAP)$1.55$0.84$2.24$2.29$3.31
YoY %+4.7%-45.8%+166.7%+2.2%+44.5%